Guaifenesin

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients with respiratory conditions. It helps to loosen phlegm and thin bronchial secretions, thereby making coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are advised to take 2 to 4 teaspoonfuls every 4 hours, not exceeding 6 doses within a 24-hour period. For children aged 6 years to under 12 years, the recommended dosage is 1 to 2 teaspoonfuls every 4 hours, also adhering to the maximum limit of 6 doses in a 24-hour period.

For children aged 2 years to under 6 years, the dosage is 1/2 to 1 teaspoonful every 4 hours, with the same restriction on total daily doses. It is important to consult a physician for children under 2 years of age regarding appropriate dosing.

Healthcare professionals should ensure that patients are aware of the dosing intervals and the importance of not exceeding the recommended maximum daily doses.

Contraindications

There are no specified contraindications for this product. However, it is essential to adhere to the recommended dosage guidelines. Use of the product in excess of the directed amount is not advised.

Warnings and Precautions

It is imperative that healthcare professionals advise patients to consult a physician prior to use if they present with a cough characterized by excessive phlegm (mucus) or if the cough is chronic, as seen in conditions such as smoking, asthma, chronic bronchitis, or emphysema.

Patients should be cautioned against exceeding the recommended dosage. Adherence to the prescribed amount is essential to ensure safety and efficacy.

In instances where the cough persists for more than 7 days, recurs, or is accompanied by additional symptoms such as fever, rash, or a persistent headache, patients must discontinue use and seek medical advice. These symptoms may indicate a more serious underlying condition that requires further evaluation.

In the event of an overdose, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay. Prompt action is crucial in managing potential overdose situations effectively.

Side Effects

Patients should be advised to stop use and consult a healthcare professional if their cough persists for more than 7 days, returns, or is accompanied by fever, rash, or a persistent headache, as these symptoms may indicate a serious underlying condition.

Additionally, patients are encouraged to seek medical advice prior to use if they have a cough associated with excessive phlegm (mucus) or if they experience a chronic cough, which may be related to smoking, asthma, chronic bronchitis, or emphysema.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Guaifenesin. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should consult a healthcare professional before use. For children aged 2 to under 6 years, the recommended dosage is 1/2 to 1 teaspoonful every 4 hours. In children aged 6 years to under 12 years, the dosage increases to 1 to 2 teaspoonfuls every 4 hours.

For adolescents and adults aged 12 years and older, the dosage is 2 to 4 teaspoonfuls every 4 hours. It is important to note that no more than 6 doses should be taken within a 24-hour period.

This product should be kept out of reach of children. In the event of an overdose, immediate medical assistance should be sought, or contact a Poison Control Center.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be vigilant in monitoring for symptoms that may arise from an overdose. While specific symptoms are not detailed in the provided information, it is essential to be aware that they can vary based on the substance involved and the individual patient’s response.

Management of an overdose typically involves supportive care and symptomatic treatment. Healthcare providers should ensure that the patient is stabilized and closely monitored throughout the treatment process. It is advisable to follow established protocols for overdose management, which may include administering activated charcoal if appropriate and ensuring the patient’s safety during the recovery phase.

In summary, immediate action and appropriate medical intervention are critical in the case of an overdose to ensure the best possible outcome for the patient.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Patients should be advised to seek immediate medical assistance or contact a Poison Control Center in the event of an overdose. It is important for patients to stop using the product and consult a healthcare provider if their cough persists for more than 7 days, returns, or is accompanied by symptoms such as fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

Patients should be instructed to adhere strictly to the recommended dosage and not exceed the directed amount while using this product. Additionally, it is essential for patients to consult a healthcare provider prior to use if they have a cough that is associated with excessive phlegm (mucus). Furthermore, patients should be encouraged to seek medical advice if they have a cough that is chronic or lasts for an extended period, particularly if it is related to smoking, asthma, chronic bronchitis, or emphysema.

Storage and Handling

The product is supplied with a tamper-evident seal under the cap, ensuring the integrity of the packaging. It should be stored at a controlled room temperature of 20° to 25°C (68° to 77°F) to maintain its efficacy and safety. Proper storage conditions are essential to preserve the quality of the product throughout its shelf life.

Additional Clinical Information

The medication is administered orally. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. It is also important to instruct patients to keep the medication out of reach of children and to seek medical assistance or contact a Poison Control Center immediately in the event of an overdose.

Drug Information (PDF)

This file contains official product information for Guaifenesin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)